The ability of different forms of heparins to suppress P-selectin function in vitro correlates to their inhibitory capacity on bloodborne metastasis in vivo

Ralf J. Ludwig; Susanne Alban; Roxana Bistrian; Wolf-Henning Boehncke; Roland Kaufmann; Reinhard Henschler; Jens Gille

doi:10.1160/TH05-07-0515

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2006; 95(03): 535-540
DOI: 10.1160/TH05-07-0515

Cellular Proteolysis and Oncology

Schattauer GmbH

The ability of different forms of heparins to suppress P-selectin function in vitro correlates to their inhibitory capacity on bloodborne metastasis in vivo

Authors

Ralf J. Ludwig

¹Department of Dermatology, Johann Wolfgang Goethe-University, Frankfurt am Main, Germany
Susanne Alban

²Pharmaceutical Institute, Christian-Albrechts-University, Kiel, Germany
Roxana Bistrian

³Institute for Transfusion Medicine and Immune Hematology, German Red Cross Blood Donor Service, Johann Wolfgang Goethe-University, Frankfurt am Main, Germany
Wolf-Henning Boehncke

¹Department of Dermatology, Johann Wolfgang Goethe-University, Frankfurt am Main, Germany
Roland Kaufmann

¹Department of Dermatology, Johann Wolfgang Goethe-University, Frankfurt am Main, Germany
Reinhard Henschler

³Institute for Transfusion Medicine and Immune Hematology, German Red Cross Blood Donor Service, Johann Wolfgang Goethe-University, Frankfurt am Main, Germany
Jens Gille

¹Department of Dermatology, Johann Wolfgang Goethe-University, Frankfurt am Main, Germany

Abstract

Summary

Ample evidence suggests that many of the in vivo anti-metastatic effects by heparins reflect their actions on P-selectin-mediated binding. We hypothesized that the ability of widely used heparins and derivatives to interfere with P-selectin-dependent tumour cell interactions under flow in vitro could be used to identify anticoagulants with advanced inhibitory functions on experimental blood-borne metastasis in vivo. To test this assumption, the impact of unfractionated heparin, the low-molecular-weight heparins (LMWH) nadroparin and enoxaparin, and the synthetic pentasaccharide fondaparinux on P-selectin-dependent tumour interactions in vitro and metastasis formation in vivo were evaluated. Our data revealed that these commonly used anticoagulants widely differ in their potential to interfere with P-selectinmediated cell binding. Importantly, the superior inhibitory capacity on P-selectin function of unfractionated heparin and LMWH nadroparin as opposed to LMWH enoxaparin and synthetic heparin pentasaccharide fondaparinux strongly correlated to the inhibitory potency of each in inhibiting experimental lung metastasis in vivo. Hence, P-selectin inhibition may constitute a valuable feature to identify anticoagulants that are suitable for anticancer therapy.

Keywords

Anticoagulants - heparin - P-selectin - neoplasm metastasis - melanoma

Full Text

References

References
1 Chambers AF, Groom AC, MacDonald IC. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2002; 02: 563-72.
2 Smorenburg SM, Van Noorden CJ. The complex effects of heparins on cancer progression and metastasis in experimental studies. Pharmacol Rev 2001; 53: 93-105.
3 Borsig L, Wong R, Feramisco J. et al. Heparin and cancer revisited: mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumour metastasis. Proc NatlAcad Sci USA 2001; 98: 3352-7.
4 Nelson RM, Cecconi O, Roberts WG. et al. Heparin oligosaccharides bind Land P-selectin and inhibit acute inflammation. Blood 1993; 82: 3253-8.
5 Koenig A, Norgard-Sumnicht K, Linhardt R. et al. Differential interactions of heparin and heparan sulfate glycosaminoglycans with the selectins. Implications for the use of unfractionated and low molecular weight heparins as therapeutic agents. J Clin Invest 1998; 101: 877-89.
6 Ludwig RJ, Boehme B, Podda M. et al. Endothelial P-selectin as a target of heparin action in experimental melanoma lung metastasis. Cancer Res 2004; 64: 2743-50.
7 Pineo GF, Hull RD. Unfractionated and low-molecular-weight heparin. Comparisons and current recommendations. Med Clin North Am 1998; 82: 587-99.
8 Gould MK, Dembitzer AD, Doyle RL. et al. Lowmolecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials. Ann Intern Med 1999; 130: 800-9.
9 Turpie AG, Eriksson BI, Lassen MR. et al. Fondaparinux, the first selective factor Xa inhibitor. Curr Opin Hematol 2003; 10: 327-32.
10 Alban S. From heparins to factor Xa inhibitors and beyond. Eur J Clin Invest 2005; (35) (Suppl. 01) 12-20.
11 Lee AY, Rickles FR, Julian JA. et al. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol 2005; 23: 2123-9.
12 Klerk CP, Smorenburg SM, Otten HM. et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol 2005; 23: 2130-5.
13 Casu B, Gennaro U. A conductimetric method for the determination of sulphate and carboxyl groups in heparin and other mucopolysaccharides. Carbohydr Res 1975; 39: 168-76.
14 Jager E, Karbach J, Gnjatic S. et al. Identification of a naturally processed NY-ESO-1 peptide recognized by CD8+ T cells in the context of HLA-B51. Cancer Immunity 2002; 02: 12.
15 Hopfner M, Alban S, Schumacher G. et al. Selectinblocking semisynthetic sulfated polysaccharides as promising anti-inflammatory agents. J Pharm Pharmacol 2003; 55: 697-706.
16 Richter R, Bistrian R, Escher S. et al. Quantum proteolytic activation of chemokine CCL15 by neutrophil granulocytes modulates mononuclear cell adhesiveness. J Immunol 2005; 175: 1599-608.
17 Kaur J, Woodman RC, Ostrovsky L. et al. Selective recruitment of neutrophils and lymphocytes by thrombin: a role for NF-kappaB. Am J Physiol Heart Circ Physiol 2001; 281: H784-95.
18 Gill V, Doig C, Knight D. et al. Targeting adhesion molecules as a potential mechanism of action for intravenous immunoglobulin. Circulation 2005; 112: 2031-9.
19 Mannori G, Crottet P, Cecconi O. et al. Differential colon cancer cell adhesion to E-, P-, and L-selectin: role of mucin-type glycoproteins. Cancer Res 1995; 55: 4425-31.
20 Borsig L, Wong R, Hynes RO. et al. Synergistic effects of L-and P-selectin in facilitating tumour metastasis can involve non-mucin ligands and implicate leukocytes as enhancers of metastasis. Proc Natl Acad Sci USA 2002; 99: 2193-8.
21 Nakamori S, Kameyama M, Imaoka S. et al. Increased expression of sialyl Lewisx antigen correlates with poor survival in patients with colorectal carcinoma: clinicopathological and immunohistochemical study. Cancer Res 1993; 53: 3632-7.
22 Nakayama T, Watanabe M, Katsumata T. et al. Expression of sialyl Lewis(a) as a new prognostic factor for patients with advanced colorectal carcinoma. Cancer 1995; 75: 2051-6.
23 Jorgensen T, Berner A, Kaalhus O. et al. Up-regulation of the oligosaccharide sialyl LewisX: a new prognostic parameter in metastatic prostate cancer. Cancer Res 1995; 55: 1817-9.
24 Numahata K, Satoh M, Handa K. et al. Sialosyl- Le(x) expression defines invasive and metastatic properties of bladder carcinoma. Cancer 2002; 94: 673-85.
25 Kim YJ, Borsig L, Varki NM. et al. P-selectin deficiency attenuates tumour growth and metastasis. Proc Natl Acad Sci USA 1998; 95: 9325-30.
26 Zacharski LR, Ornstein DL. Heparin and cancer. Thromb Haemost 1998; 80: 10-23.
27 Sciumbata T, Caretto P, Pirovano P. et al. Treatment with modified heparins inhibits experimental metastasis formation and leads, in some animals, to long-term survival. Invasion Metastasis 1996; 16: 132-43.
28 Wang L, Brown JR, Varki A. et al. Heparin’s anti-inflammatory effects require glucosamine 6-O-sulfation and are mediated by blockade of L- and P-selectins. J Clin Invest 2002; 110: 127-36.
29 Esko JD, Lindahl U. Molecular diversity of heparan sulfate. J Clin Invest 2001; 108: 169-73.